MedTrace Logo

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

NCT01191684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-08-01

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with colorectal, stomach, or pancreatic cancer.

Conditions

  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Pancreatic Cancer
  • Recurrent Rectal Cancer
  • Stage III Colon Cancer
  • Stage III Gastric Cancer
  • Stage III Pancreatic Cancer
  • Stage III Rectal Cancer
  • Stage IV Colon Cancer
  • Stage IV Gastric Cancer
  • Stage IV Pancreatic Cancer
  • Stage IV Rectal Cancer

Interventions

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

flow cytometry

Correlative studies

OTHER

immunoenzyme technique

Correlative studies

BIOLOGICAL

modified vaccinia virus ankara vaccine expressing p53

Given SC

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Vincent Chung, MD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01191684 on ClinicalTrials.gov